Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
about
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceDose-dense adjuvant chemotherapy for primary breast cancer.8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003Progress in adjuvant chemotherapy for breast cancer: an overviewAn EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term resultsIs Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?Management of breast cancer in the older woman.The expanding role of epirubicin in the treatment of breast cancer.Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis.Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients.Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancersHigh rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer.Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes.Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.The analysis of relapse-free survival curves: implications for evaluating intensive systemic adjuvant treatment regimens for breast cancerEvaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extractA randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.Complications following breast cancer therapy in the adult spina bifida population: A case report.Chemotherapy for early-stage breast cancer: a brief history.Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy.MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast canThe Results of Chemotherapy with Two Variants of Intravenous CMF in Patients with Early Stage Breast Carcinoma; Does Dose Density Matter?Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement.A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
P2860
Q24792539-7D490382-21A5-40BF-9457-99C68460945EQ24797259-F780B144-0211-496D-837F-456341B82D8FQ24803899-85F2A35F-D4A2-43DC-8428-1121B75DDD94Q26798078-21FE00E8-9C48-48B1-95A5-B0536B645CCFQ33340401-1B3426EE-60AC-4C84-9872-FBEFE67049F4Q33369478-FEC68430-734E-4862-8FD0-8F364D39F408Q33397922-347CEDCB-9718-4CC0-A526-A80FEDEFEF4CQ34095821-E8A9191F-A7D9-462B-910D-FFA7C109E38CQ34386713-55D6F88E-DB0D-4B81-8917-F2296D0BA32CQ34608626-F2C2F786-91A0-4439-B23F-298B0DEB56BBQ34725707-4290B518-0023-4C45-84F0-B963B9CB79E9Q35596990-9D556A15-39EC-4D44-BA21-926977B3C497Q35602282-003A42FF-BBCA-46DF-BB78-C32B7A7162FDQ35623087-387118A8-97A5-4921-B89F-CC7030A28530Q35692392-167048E5-3773-4F5A-88E0-1DD5F0A55B13Q35807180-D3B17AFD-C36A-4E50-987B-A77D1F3C2016Q35879081-D7156E52-7986-4977-96B5-6F5BB6C59C98Q36111489-5024DF9C-C58C-4134-BBE2-832B5C07221AQ36379148-4F7B9137-2409-43E3-94A5-0E2470830F8CQ36484592-6DD8B57B-C226-4706-BF39-AE4AFDF44BE6Q36485208-EF2075BB-6E14-4B87-BB67-65B507CF1DFAQ36609419-40FC5B75-9340-4F44-BEB3-1D424027E459Q36615818-B0EDB3C9-332B-4DC7-A698-73F369D5B0B8Q37014753-5DF413D7-9162-4E9E-98D1-52741FCF1E3FQ37081127-A36E4471-C94C-4F2A-8B5F-D2918A974B51Q37342912-494DF7D4-1E19-4C84-BAE6-BC25C82B2C7BQ37363341-99F4D6C8-D3C3-4A80-913C-FFEDB0DDA247Q37657782-F2EB650B-1F69-4C7E-8EC7-703207B51E48Q38005345-3CCCD23E-BE0C-4FC3-BFA1-336973A60B3DQ38109529-72B56953-0482-448F-8A0C-6805DFF9A6FCQ38682028-B6DFB135-BBB6-4644-B103-4972AB046983Q40127291-15DF818F-1F74-4F50-A4B5-BCB0F9E9A82CQ40137270-EC4BB70C-6E9E-419F-B10E-971A1E28BC93Q40316147-7DEAB936-2650-4E2F-8069-F489B62AABE8Q40320494-76547910-5688-4CF1-9818-745D2106407BQ40420167-1DA49B15-E86D-4E73-8B56-07C1026C78C6Q40554971-537321CF-8028-418F-9569-1AC621CC2103Q40615462-29344893-E8A6-4907-ADB5-B534152EBC6AQ41294757-9FD960E5-243C-44FD-AE25-7D54AEBB10B0Q46536361-AE94C582-BE8C-4D33-97F8-316FF970D496
P2860
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@ast
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@en
type
label
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@ast
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@en
prefLabel
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@ast
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@en
P1476
Benefit of a high-dose epirubi ...... udy Group 05 randomized trial.
@en
P2093
French Adjuvant Study Group
P304
P356
10.1200/JCO.2001.19.3.602
P407
P577
2001-02-01T00:00:00Z